Efficacy and safety of BRAF-MEK inhibitors in treatment of Chinese patients with papillary craniopharyngioma: A retrospective cohort study [0.03%]
BRAF-MEK抑制剂治疗中国患者垂体乳头状颅咽管瘤疗效和安全性：回顾性队列研究
Rui Han,Xiaorong Yan,Boyuan Yao et al.
Rui Han et al.
Previous research supports the efficacy of BRAF-MEK inhibitor therapy for papillary craniopharyngiomas (PCPs). This retrospective study of 30 Chinese PCP patients evaluated tumor response and safety outcomes during treatment. All patients m...
Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing [0.03%]
高效编辑肿瘤浸润淋巴细胞中的基因
Morteza Hafezi,Raphael Genolet,Leila Hadadi et al.
Morteza Hafezi et al.
The disruption of immune checkpoints in T cells is a promising tool for improving the efficacy of tumor-infiltrating lymphocyte (TIL) therapy. While CRISPR-Cas9 genome-editing is efficient, Cas9 nucleases induce double-strand DNA breaks and...
An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma [0.03%]
一种携带IL-12的溶瘤型单纯疱疹病毒治疗脑胶质母细胞瘤的小鼠模型和犬科动物模型研究
Joseph W Jackson,Bonnie L Hall,Chaim Sneiderman et al.
Joseph W Jackson et al.
Glioblastoma (GBM) is a devastating brain cancer with a 5-year survival rate of ∼5% despite current treatment regimens. Multiple oncolytic herpes simplex viruses (oHSV) have been designed for GBM therapy, but clinical trials have thus far ...
Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus [0.03%]
福司替尼(R788)，一种脾酪氨酸激酶抑制剂，可增强胰腺癌细胞对溶瘤VSV的敏感性
Cassandra Catacalos-Goad,Dakota W Goad,Molly C Holbrook et al.
Cassandra Catacalos-Goad et al.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with limited treatment options. Oncolytic virus (OV) therapy exploits replication-competent viruses, including vesicular stomatitis virus (VSV), to preferentiall...
Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors [0.03%]
针对HER2阳性实体瘤的纳米抗体基CAR-T细胞的临床前开发和选择
Fien Meeus,Arne Van der Vreken,Dorien Autaers et al.
Fien Meeus et al.
Chimeric antigen receptor (CAR)-T cell therapy revolutionized treatment of hematological malignancies, but translation to solid tumors remains difficult. Therefore, different avenues are explored to develop novel CAR-T cell products. Nanobo...
Akt inhibition enhances the antitumor efficacy of immune checkpoint blockades and radiotherapy in a syngeneic breast cancer model [0.03%]
AKT抑制增强免疫检查点阻滞和放射治疗在同基因小鼠乳腺癌模型中的抗肿瘤疗效
Nawon Park,Seung Hyuck Jeon,Yoomin Kim et al.
Nawon Park et al.
Immune checkpoint blockades (ICBs) have limited efficacy against immunologically cold breast cancers. Although radiotherapy (RT) can potentiate antitumor immunity, many patients fail to benefit, partly due to activation of immunosuppressive...
Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death [0.03%]
近红外光免疫治疗通过诱导免疫源性细胞死亡有效清除卵巢癌细胞
T M Mohiuddin,Chaoyu Zhang,Wenjie Sheng et al.
T M Mohiuddin et al.
Ovarian cancer represents one of the most common forms of female gynecological cancer. The existing treatment modalities include surgery and chemotherapy, which are unable to treat local and long-distant micro-metastases. Near-infrared phot...
CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial [0.03%]
白俄罗斯儿童和成人复发或难治性B细胞肿瘤患者中BY19(CD19 CAR-T)治疗：I期临床试验
Mikalai Katsin,Dmitri Dormeshkin,Alexandr Migas et al.
Mikalai Katsin et al.
Access to chimeric antigen receptor (CAR) T cell therapy remains limited in many developing countries. We conducted a single-arm, open-label, phase 1 trial (NCT05333302) at two Belarusian centers, evaluating an in-house manufactured CD19 CA...
Pre-clinical evaluation of a potent and effective Pin1-degrading agent in pancreatic cancer [0.03%]
胰腺癌中有效的Pin1降解剂的临床前评估
Giulia Alboreggia,Tiane Li,Anne Marie Prentiss et al.
Giulia Alboreggia et al.
The peptidyl-prolyl isomerase protein Pin1 has been shown to contribute to cancer onset, development, and progression by regulating the function and stability of oncogenes and tumor suppressors, both in cancer cells and surrounding stromal ...